Bolt Biotherapeutics Inc. held its 2025 annual meeting of stockholders on May 27, 2025. During the meeting, director nominees Laura Berner and Brian O'Callaghan were elected to the board of directors. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the certificate of incorporation to effect a reverse stock split of the company's issued and outstanding common stock was also approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-077880), on May 28, 2025, and is solely responsible for the information contained therein.